• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Why Delay the Control of Modifiable Vascular Risk Factors (MVRF) Until the Occurrence of an Ischemic Stroke (iStroke)? (P1.180)
Conclusions: We found that the management of MVRF increases after the first ischemic event and this improves the early prognosis of iStroke (Rankin-based disability). It is important to improve the management of these factors in the setting of primary prevention.Disclosure: Dr. Pagano Ajolfi has nothing to disclose. Dr. Sanz has nothing to disclose. Dr. Alfonso has nothing to disclose. Dr. Seijas has nothing to disclose. Dr. Arrébola has nothing to disclose. Dr. Giannaula has received personal compensation for activities with Boehringer Ingelheim.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Pagano Ajolfi, S., Sanz, P., Alfonso, A., Seijas, M., Arrebola, M., Giannaula, R. Tags: Cerebrovascular Disease: Risk Factors and Prevention Source Type: research

Clinical Reasoning: A 66-year-old man with recurrent multi-territory infarcts
A 66-year-old man was referred to our center for evaluation of recurrent infarcts in multiple vascular territories over the preceding 6 months (figure 1). The patient first presented with a 3-month, stuttering course of transient neurologic deficits, including right arm and leg hemiparesis, expressive aphasia, and right homonymous hemianopia. He was initially evaluated at a community Stroke Prevention Clinic. His medical history was significant for several classic vascular risk factors: coronary artery disease requiring a coronary artery bypass graft, dyslipidemia for which he was taking atorvastatin 20 mg daily, and obstr...
Source: Neurology - June 8, 2015 Category: Neurology Authors: Kouzmitcheva, E., Steriade, C., Prica, A., Hazrati, L.-N., Mandell, D. M. Tags: All Cerebrovascular disease/Stroke, All Education RESIDENT AND FELLOW SECTION Source Type: research

Does hospitalist directed care reduce the length of stay for acute ischemic stroke patients and improve adherence to the "Get with the Guidelines" inpatient quality measures? (P5.153)
CONCLUSIONS: There is a significant improvement in adherence to the GWTG-ISPM when an AIS patient is admitted under the care of a hospitalist. Prospective databases are recommended to evaluate if this leads to better long-term outcomes.Disclosure: Dr. Tekle has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Sanchez has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Abantao has nothing to disclose. Dr. Sanchez has nothing to disclose. Dr. Jones-Fillingum has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Tekle, W., Hassan, A., Sanchez, C., Malik, A., Abantao, E., Sanchez, O., Jones-Fillingum, L., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Quality Research and Initiatives Source Type: research

Factors predictive of hospice care in patients with Ischemic stroke (P1.077)
CONCLUSIONS: In our patient population, factors associated with hospice discharge were female gender, age > 70 years, prior stroke and not receiving thrombolysis and/ or intervention. Severity of deficits (NIHSS) was not a reliable marker. Study Supported by:Disclosure: Dr. Sultan has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Sultan, F., Lee, J. Tags: Cerebrovascular Disease and Interventional Neurology: Epidemiology Source Type: research

Quality Assessment of Vascular Disease Prevention Practices in High Risk Urban Women (P7.139)
CONCLUSIONS: Despite their proven value for secondary prevention, antiplatelet therapy and statins were underutilized in women with prior stroke or TIA. Strategies to intensify vascular disease prevention in high risk urban women and particularly women under 70 are needed. Study Supported by:Pfizer Disclosure: Dr. Chaturvedi has received personal compensation for activities with Genentech, Inc., Abbott Vascular, Boehringer-Ingelheim, WL Gore, and Merck. Dr. Chaturvedi has received personal compensation in an editorial capacity for NEJM Journal Watch Neurology. Dr. Pieper has nothing to disclose. Dr. Levine ha...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Chaturvedi, S., Pieper, D., Levine, D., Thati, N., Madhavan, R., Mateo, M., Cardozo, L., Lepczyk, M. Tags: Cerebrovascular Disease and Interventional Neurology: Race, Ethnicity, and Stroke Source Type: research

Primary Prevention of Stroke in Argentina: a Missed Opportunity? Data from the ARENAS Registry (P1.111)
CONCLUSIONS: this study provides data on stroke risk factors prevalence and control in an Argentine cohort. Our results show a high percentage of at-risk patients without adequate control in the primary prevention setting, denoting a missing opportunity to reduce the burden of stroke.Disclosure: Dr. Atallah has nothing to disclose. Dr. Fustinoni has nothing to disclose. Dr. Beigelman has nothing to disclose. Dr. Zurru has nothing to disclose. Dr. Ameriso has nothing to disclose. Dr. Cirio has nothing to disclose. Dr. Burry has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Atallah, A., Fustinoni, O., Beigelman, R., Zurru, M., Ameriso, S., Cirio, J., Burry, G. Tags: Cerebrovascular Disease and Interventional Neurology: Antiplatelet Agents and Miscellaneous Source Type: research

Predictors of Good Clinical Outcome in Acute Stroke Patients Underwent Recanalization Therapy (P01.242)
CONCLUSIONS: NIHSS at admission, recanalization grade and early neurological improvement are independent predictors of clinical outcome in AIS patients underwent mechanical recanalization.Supported by: IGA MH CR grants NT/11386-5/2010, NT/11046-6/2010, NT/13498-4/2012.Disclosure: Dr. Skoloudik has nothing to disclose. Dr. Roubec has nothing to disclose. Dr. Kuliha has nothing to disclose. Dr. Herzig has received personal compensation for activities with Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., and Gedeon Richter. Dr. Sanak has received personal compensation from Boehringer Ingelheim for serving on a scientific ad...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Skoloudik, D., Roubec, M., Kuliha, M., Herzig, R., Sanak, D., Prochazka, V., Hrbac, T. Tags: P01 Cerebrovascular Disease I Source Type: research